A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Breast Neoplasms
Both
Breast Neoplasms
Trial Information
A Phase 1 Study Of Paclitaxel In Combination With SU011248 For Patients With Breast Cancer As First-Line Treatment In The Advanced Disease Setting
Inclusion Criteria:
- Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.
- Candidate for treatment with paclitaxel.
Exclusion Criteria:
- Prior chemotherapy in the advanced disease setting.
- HER2 positive disease unless previously treated with trastuzumab.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety of the combination of SU011248 and paclitaxel
Outcome Time Frame:
9/05-7/07
Safety Issue:
No
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
A6181073
NCT ID:
NCT00174434
Start Date:
September 2005
Completion Date:
August 2007
Related Keywords:
- Breast Neoplasms
- Breast Neoplasms
- Neoplasms
Name | Location |
|---|---|
| Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
| Pfizer Investigational Site | Bronx, New York 10461 |
| Pfizer Investigational Site | Carmel, Indiana 46032 |
